Smoking cessation most effective when smokers have person-to-person support, data shows
CHICAGO Recent meta-analysis research published Monday in the Archives of Internal Medicine found that smoking cessation programs offered to hospitalized smokers is most effective if supportive contacts remain in contact with that smoker for more than one month following discharge.
Smoking counseling that began during hospitalization and included supportive contacts for more than 1 month after discharge increased smoking cessation rates at 6 to 12 months, versus no benefit with those interventions with less post-discharge contact. Adding nicotine replacement therapy to counseling improved results.
Alcon reports third-quarter eye care sales increase
HUNENBERG, Switzerland Alcon Thursday morning reported an increase in consumer eye care sales of 10.5 percent to $223.7 million for its third quarter ended Sept. 30. Sales of contact lens disinfectants grew 2.6 percent, as Opti-Free RepleniSH and Opti-Free Express multipurpose disinfecting solutions continued to maintain their combined market share in the United States.
Alcon currently fields a 38.7 percent market share of the U.S. contact lens care license market, the company reported, remaining the only branded marketer to own a greater market share than private label alternatives and exceeding market share of competitors Bausch & Lomb and AMO, which together possess less than 25 percent market share. “We gained significant market share on a global basis as a result of the product recalls by competitors in 2006 and 2007,” commented Cary Rayment, Alcon chairman, president and chief executive officer during a conference call with analysts. “We have been able to maintain the share we gained in the past two years,” he said.
“We are the only brand that exceeds private label in the U.S.,” he added. “We believe this is a result of our success in communicating the efficacy and safety of the Opti-Free RepleniSH brand to the professional channel where we get about seven out of 10 recommendations from optometrists in the U.S.”
Sales of artificial tears products increased 28 percent, led by increases in the global sales of Systane lubricant eye drops and the U.S. launch of Systane Ultra in July. “Quarterly sales have almost tripled in the last five years, reflecting increased market demand and market share gains in this segment,” Rayment said.
Alcon reported global sales of $1.5 billion for the third quarter, an increase of 14.1 percent.
Retailers reworking planograms in lieu of children’s cough-cold remedy debacle
NEW YORK With the industry’s announcement that future labeling for kids cough-cold products would recommend use of those products in children only over the age of four, and that those products carrying the old labeling would sell through before being replaced with the new labeling, coupled with widespread criticism from Congress leaders and citizen advocacy groups that that voluntary measure doesn’t go far enough, purveyors of pediatric cough-cold remedies are in for another stormy season.
Last year, the Consumer Healthcare Products Association in October initiated a voluntary recall of all cold products marketed for use in infants—in other words, children under the age of two—just a few weeks before the Food and Drug Administration hosted a joint advisory meeting entertaining a citizen’s petition that would ban use of those cold products in all children under the age of six. From purely a business standpoint (to be clear, both CHPA and individual suppliers have repeatedly emphasized a focus on child safety in their advocacy of appropriate access to, and appropriate use of, these medicines, not profits), the timing couldn’t have been worse. October is oftentimes identified as the first month of the cough-cold season. Retailers at that time are about a month into the new season’s cough-cold planograms and suppliers begin advertising those cough-cold products in earnest. Compounding matters, the FDA in mid-January 2008 issued a public advisory against marketing cough-cold products for use in infants, which brought the issue again to top-of-mind among consumers just as actual cough-cold illness rates started picking up.
And while it’s difficult to ascertain just how much the timing of the actual under-two product recall, meetings and announcements impacted the actual business of pediatric cough-cold medicines, there has been an impact. Sales of kids cough-cold products dropped 8.5 percent to $287 million across food, drug and mass channels (minus Wal-Mart) for the 52 weeks ending Oct. 4, according to sales data from the Nielsen Company. That compares to a 12.1 percent lift in sales of adult cough/cold formulations sold over-the-counter, the lion’s share of which can be attributed to the crossover of McNeil’s Zyrtec from prescription to nonprescription, but still that suggests that the decline in kids cough-cold sales is more likely attributed to the confusion created by all those news stories questioning the safety and efficacy of these medicines as opposed to a mild cough-cold season.
Fast-forward to the 2008/2009 cough-cold season. Another October FDA meeting—this time a public meeting requesting comments on what changes should be made, if any, to the monographs governing the vast majority of these pediatric cough/cold products—threatens to scuttle sales of pediatric cough/cold medicines before the season really kicks off. CHPA, through negotiations with FDA, has volunteered to change label recommendations of cough/cold medicines to “do not use” in children under the age of four. FDA precedent surrounding voluntary label changes has allowed industry to allay the cost associated with replacing one label for another by selling through those products carrying the old labels. But the FDA is being pressured by some Congress leaders to act more aggressively regarding this label change—opening the door to the possibility that a second product recall in as many years may be forced upon the kids cough/cold industry.
The costs associated with removing those products out of the supply chain could run into the tens of millions across the industry, one supplier of those cough/cold products predicted, suggesting that any recall would result in millions of dollars in direct losses, as products are pulled off of shelves and out of the supply chain to be destroyed, for each manufacturer in the business, as well as for each retailer given the prevalence of private label offerings in the kids cold category.
Not all is doom and gloom, however. Several manufacturers are currently positioning their products as alternatives to appropriately relieve cold symptoms in younger children—products that will allay parent concerns over the use of allopathic medicines in their pre-school children and older and, if it actually comes to a product recall, will help fill that empty space created by the 100 or so SKUs that would be impacted by that recall.
Chief among those manufacturers are suppliers of homeopathic remedies. According to homeopathic suppliers, homeopathic cough, cold and flu medicines do not contain any of the ingredients under question for use in young children. The active ingredients are micro-doses of natural ingredients. And since homeopathic medicines are not body-mass dependent, there’s no need to give more or less medicine depending on body weight. There’s no risk of overdose, nor are there reported side effects such as making children jittery or drowsy. The medicines do not interact with other medications, herbs or supplements and do not “mask” symptoms that may indicate a more serious condition. Another positive—all homeopathic products are regulated as drugs by the FDA and are labeled for specific indications.
“Natural cough and cold medicines for children are not simply recent industry fads, but rather time-tested medications that are highly safe and effective,” stated Jim Sears, an expert in the field of pediatric medicine and advocate of natural medicines. “By being completely free of the active ingredients of concern to the FDA, homeopathic medicines provide symptom relief for children and peace of mind for parents everywhere.”
“It all comes down to understanding what you put into your body and the bodies of your children,” added J. P. Borneman, chairman and chief executive officer of Hyland’s. “At Hyland’s we create the types of children’s medications that we feel safe giving to our own kids. Our medicines treat the cause of sickness safely and gently, without fear of side effects, and are manufactured according to FDA’s Good Manufacturing Practices.”
Hyland’s launched a complete line of products to treat the cough and cold symptoms of children, including: Cough Syrup with 100 percent Natural Honey 4 Kids; Cold ‘n Cough 4 Kids, New; Cold Relief with Zinc 4 Kids Strips, due in stores this winter; Sniffles ‘n Sneezes 4 Kids; Complete Flu Care 4 Kids; C-Plus Cold Tablets; Cough Syrup with Honey; and Earache Drops.
“If parents take anything away from this situation, they should understand that they are their child’s greatest defense against avoiding the dangers associated with the OTC medications causing concern,” Sears said. “Parents need to make sure they are educated on the benefits of natural medicines available to them and their children so they are not forced to decide between treating their child’s sickness and keeping their child safe.”
Boiron this year has launched two new SKUs—Children’s Oscillococcinum for flu-like symptoms and Children’s Coldcalm Pellets for colds, which will be marketed alongside Boiron’s Children’s Chestal for coughs. “We created special packaging for Children’s Oscillococcinum and Children’s Coldcalm Pellets to make it easier for parents find these safe choices,” John Durkin, Boiron’s vice president, sales and marketing, said. “Now both products will be located in the children’s cough-cold and flu section and the packaging highlights important product benefits that will help parents treat their children’s symptoms—messages like ‘safe, no side effects, great taste, and easy to take,’” he said. “We’ve also modify the delivery method of our regular Coldcalm tablets so the children’s version of it and Oscillococcinum come in sweet-tasting kid-friendly pellets.”
Other treatment alternatives include drug-free devices that help increase a child’s air flow naturally, such as GlaxoSmithKline’s Breathe Right Kids, and devices such as Kaz’s Vicks-branded humidifiers.
Additionally, a recent study in healthy children found that Breathe Right Kids nasal strips help children breathe better by improving airflow when lying down to go to sleep. Findings also indicated that the strips are well-tolerated by children, comfortable to wear and easy to remove.
“Other simple drug-free remedies such as humidifiers or vaporizers, and Breathe Right Kids nasal strips all stand to provide nasal congestion relief while giving parents an alternative to over-the-counter cold medications for nasal congestion,” commented Jennifer Shu, co-author of parenting books published by the American Academy of Pediatrics.
The Mayo Clinic recommends using a humidifier to maintain daily moisture levels at 40 to 50 percent in the home. When children are suffering from a cold or cough, a higher humidity level will often increase their comfort and help ease congestion. Vicks offers a number of humidifiers to help parents and kids get through this cold season, the company stated in a recent press release issued soon after the latest FDA meeting.
Other alternatives include dietary supplements that can help boost immunity health, as well as help improve the function of healthy sinus and respiratory in children. Bionorica this year introduced its Sinupret for Kids syrup, a plant-based product supported by substantial clinical trials for its appropriate use in children.
Sinupret is also one of the first dietary supplements to partner with the venerable Walt Disney Company, a family entertainment company known for zealously guarding their brand image, according to Scott Bukow, Bionorica president. Bukow said that his company will be distributing free samples of Sinupret at several Disney on Ice events this season.
Sinupret for Kids syrup promotes healthy drainage in the upper respiratory tract, improves airflow in the nose and supports healthy mucous clearance from the nose and sinuses.
Sinupret is cited as safe and effective in numerous peer reviews, scientific and medical journals, including American Botanical Council Clinical Guide to Herbs, Journal of Clinical Pharmacology, Phytopharmaka, Planta Medica, Natural Standards-Herbs, Pharmacist’s Letter for efficacy and safety and Natural Medicines Comprehensive Database.
Even manufacturers of traditional allopathic medicines are introducing new products into a risk-averse kids cough/cold environment. The Quigley Corporation recently introduced its new Kids-EEZE Chest Relief, a single-ingredient, allopathic expectorant with guaifenesin to help children, ages six and up, suffering from uncomfortable chest congestion. Quigley is positioning the product containing guaifenesin, which is actually one of the ingredients the safety and efficacy of which is being questioned in young children, as a single ingredient alternative to the many multi-symptom children’s cold products that could potentially lead to overmedication, the company stated.
“In recent years, the cough and cold remedy category has seen a growth in multi-symptom cold remedies, which has led to concerns about parents overmedicating their kids and treating symptoms their children weren’t actually suffering from,” said Albert Piechotta, executive director of communications and investor relations at the Quigley Corporation. “Chest congestion is a typical symptom of the common cold and one that is uncomfortable for children,” Paul Horowitz of Discovery Pediatrics in Valencia, Calif. said. “Making a cough more productive can really make the child feel better and reduce the chances of that chest congestion turning into something more serious.”